Search Filters

Search Results

Found 2 results

510(k) Data Aggregation

    K Number
    K243818

    Validate with FDA (Live)

    Date Cleared
    2025-01-08

    (27 days)

    Product Code
    Regulation Number
    880.6250
    Age Range
    All
    Reference & Predicate Devices
    Predicate For
    N/A
    AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticPediatricDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
    Intended Use

    Nitrile Powder Free Examination Glove Tested for Use with Chemotherapy Drugs and Fentanyl Citrate (Blue) is a nonsterile disposable device intended for medical purpose that is worn on the examiner's hand to prevent contamination between patient and examiner. It is also tested to be used against Chemotherapy Drugs and Fentanyl Citrate.

    Device Description

    Nitrile Powder Free Examination Glove Tested for Use with Chemotherapy Drugs and Fentanyl Citrate (Blue) is a disposable single-use, non- sterile, blue-colored and powder-free examination glove made from nitrile latex. Gloves meet the specification of ASTM D6319-19 and have been tested for resistance to permeation by chemotherapy drugs and fentanyl citrate as per ASTM D6978-05(2019).

    AI/ML Overview

    The provided text is a 510(k) Premarket Notification from the FDA for a medical device: "Nitrile Powder Free Examination Glove Tested for Use with Chemotherapy Drugs and Fentanyl Citrate (Blue)".

    This document does not describe the acceptance criteria or a study related to an AI/ML powered device. Instead, it details the testing and comparison of a physical medical device (gloves) against a predicate device, focusing on material properties, performance standards (like resistance to permeation by chemotherapy drugs and fentanyl citrate), and biocompatibility.

    Therefore, I cannot extract the requested information regarding AI/ML device acceptance criteria or related studies from this document. The questions about sample sizes, expert qualifications, adjudication methods, MRMC studies, standalone performance, ground truth, and training sets are not applicable to the type of device described in this FDA submission.

    However, I can extract the acceptance criteria and performance data for the physical device as described:

    1. Table of Acceptance Criteria and Reported Device Performance:

    The primary performance criterion for the "Nitrile Powder Free Examination Glove Tested for Use with Chemotherapy Drugs and Fentanyl Citrate (Blue)" is its resistance to permeation by chemotherapy drugs and fentanyl citrate. The acceptance criterion is a minimum breakthrough detection time for each substance.

    Chemotherapy Drug and ConcentrationAcceptance Criteria (Minimum Breakthrough Detection Time in Minutes)Reported Device Performance (Minimum Breakthrough Detection Time in Minutes)
    Carmustine, 3.3 mg/mlN/A (Tested to determine time)10.2
    Cisplatin, 1.0 mg/mlN/A (Tested to determine time)>240
    Cyclophosphamide, 20.0 mg/mlN/A (Tested to determine time)>240
    Dacarbazine, 10.0 mg/mlN/A (Tested to determine time)>240
    Doxorubicin Hydrochloride, 2.0 mg/mlN/A (Tested to determine time)>240
    Etoposide, 20.0 mg/mlN/A (Tested to determine time)>240
    Fluorouracil, 50.0 mg/mlN/A (Tested to determine time)>240
    Methotrexate, 25.0 mg/mlN/A (Tested to determine time)>240
    Mitomycin C, 0.5 mg/mlN/A (Tested to determine time)>240
    Paclitaxel, 6.0 mg/mlN/A (Tested to determine time)>240
    Thiotepa, 10.0 mg/mlN/A (Tested to determine time)30.2
    Vincristine Sulfate, 1.0 mg/mlN/A (Tested to determine time)>240
    Bleomycin Sulfate, 15.0 mg/mlN/A (Tested to determine time)>240
    Bortezomib, 1.0 mg/mlN/A (Tested to determine time)>240
    Busulfan, 6.0 mg/mlN/A (Tested to determine time)>240
    Carboplatin, 10.0 mg/mlN/A (Tested to determine time)>240
    Chloroquine, 50.0 mg/mlN/A (Tested to determine time)>240
    Cyclosporin A, 100.0 mg/mlN/A (Tested to determine time)>240
    Cytarabine, 100.0 mg/mlN/A (Tested to determine time)>240
    Daunorubicin, 5.0 mg/mlN/A (Tested to determine time)>240
    Docetaxel, 10.0 mg/mlN/A (Tested to determine time)>240
    Epirubicin, 2.0 mg/mlN/A (Tested to determine time)>240
    Fludarabine, 25.0 mg/mlN/A (Tested to determine time)>240
    Gemcitabine, 38.0 mg/mlN/A (Tested to determine time)>240
    Idarubicin, 1.0 mg/mlN/A (Tested to determine time)>240
    Ifosfamide, 50.0 mg/mlN/A (Tested to determine time)>240
    Irinotecan, 20.0 mg/mlN/A (Tested to determine time)>240
    Mechlorethamine HCI, 1.0 mg/mlN/A (Tested to determine time)>240
    Melphalan, 5.0 mg/mlN/A (Tested to determine time)>240
    Mitoxantrone, 2.0 mg/mlN/A (Tested to determine time)>240
    Oxaliplatin, 2.0 mg/mlN/A (Tested to determine time)>240
    Paraplatin, 10.0 mg/mlN/A (Tested to determine time)>240
    Retrovir, 10.0 mg/mlN/A (Tested to determine time)>240
    Rituximab, 10.0 mg/mlN/A (Tested to determine time)>240
    Topotecan, 1.0 mg/mlN/A (Tested to determine time)>240
    Trisenox, 1.0 mg/mlN/A (Tested to determine time)>240
    Fentanyl Citrate Injection, 100mcg/2mlN/A (Tested to determine time)>240

    Additional Acceptance Criteria and Performance Data (already met by similar predicate device or physical properties):

    CharacteristicAcceptance CriteriaReported Device Performance
    Freedom from holesAQL 1.5% (Meets ASTM D5151-19 and ASTM D6319-19)Pass
    Residual PowderAverage < 2 mg/glove (Meets ASTM D6319-19 & ASTM D6124-06 (2017))Pass
    Dimensional ConformanceConforms to ASTM D6319 width, thickness, and length requirements for XS, S, M, L, and XL; AQL 4%Pass
    Tensile PerformanceTensile Strength Before Aging: $\ge$ 14 MPa; Ultimate Elongation Before Aging: $\ge$ 500 %; Tensile Strength After Aging: $\ge$ 14 MPa; Ultimate Elongation After Aging: $\ge$ 400 % (Meets ASTM D6319-19); AQL 4%Pass
    Biocompatibility: Skin IrritationNot an irritant (Under the conditions of the study, per ISO 10993-10)Pass
    Biocompatibility: Skin SensitizationNot a sensitizer (Under the conditions of the study, per ISO 10993-10)Pass
    Biocompatibility: Acute ToxicityNo acute toxicity (Under the conditions of the study, per ISO 10993-11)Pass

    2. Sample size used for the test set and the data provenance:

    The document mentions that "Fentanyl citrate permeation testing was performed on the subject glove using the ASTM D6978 method." While it confirms the test was done, it does not specify the sample size for the test set used for the permeation testing.
    The data provenance is from Malaysia, where the manufacturer (Hartalega NGC Sdn. Bhd.) is located. The study appears to be prospective testing conducted specifically for this 510(k) submission.

    3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts:

    This is not applicable as the "ground truth" for this device is established through physical and chemical testing against industry standards (ASTM D6978, D6319, D5151, D6124, ISO 10993) rather than expert consensus on medical images or diagnoses.

    4. Adjudication method (e.g. 2+1, 3+1, none) for the test set:

    Not applicable, as this involves standardized physical and chemical laboratory testing, not human expert adjudication.

    5. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance:

    Not applicable. This is a medical glove, not an AI/ML-powered device.

    6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done:

    Not applicable. This is a medical glove, not an AI/ML-powered device.

    7. The type of ground truth used:

    The ground truth is established through standardized laboratory testing protocols (ASTM D6978-05, D6319-19, D5151-19, D6124-06(R17), ISO 10993-10, ISO 10993-11) and the measured chemical permeation times and physical properties of the gloves.

    8. The sample size for the training set:

    Not applicable. This is a medical glove, not an AI/ML-powered device. There is no concept of a "training set" in this context.

    9. How the ground truth for the training set was established:

    Not applicable. There is no training set for this type of device.

    Ask a Question

    Ask a specific question about this device

    K Number
    K222907

    Validate with FDA (Live)

    Date Cleared
    2023-01-04

    (100 days)

    Product Code
    Regulation Number
    880.6250
    Age Range
    All
    Reference & Predicate Devices
    Predicate For
    N/A
    AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticPediatricDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
    Intended Use

    The Nitrile Powder Free Examination Glove Tested for Use with Chemotherapy Drugs and Fentanyl Citrate is a specialty medical glove which is a disposable device intended for medical purpose that is worn on the examiner's hand or finger to prevent contamination between examiner and patient. The glove was tested for use with Chemotherapy Drugs and Fentanyl Citrate as per ASTM D6978-05 Standard Practice for Assessment of Medical Gloves to Permeation by Chemotherapy Drugs.

    Device Description

    The subject device is single use, disposable gloves intended for medical purposes to be worn on the examiner's hands to prevent contamination between patient and examiner. The gloves are powder-free, ambidextrous with beaded cuff, blue colored, nitrile, and tested for use with chemotherapy drugs and Fentanyl Citrate. The gloves are offered in five sizes: XS, S, M, L, XL. The subject device is non-sterile.

    AI/ML Overview

    This document is a 510(k) Premarket Notification for a medical device: "Nitrile Powder Free Examination Glove Tested for Use with Chemotherapy Drugs and Fentanyl Citrate." It seeks to demonstrate substantial equivalence to a legally marketed predicate device.

    The study described here is NOT for an AI/ML device, but rather for a physical medical device (examination gloves). Therefore, many of the requested items (e.g., number of experts, adjudication method, MRMC study, standalone algorithm performance, AI system effect size, sample size for training set, ground truth for training set) are not applicable to this type of device and are not present in the provided text.

    However, I can extract information related to the acceptance criteria and how the physical glove device meets those criteria.


    Table of Acceptance Criteria and Reported Device Performance

    The acceptance criteria and device performance are primarily based on established ASTM and ISO standards for examination gloves, particularly concerning physical properties, integrity, and resistance to permeation by chemotherapy drugs.

    Test Method / CharacteristicAcceptance CriteriaReported Device Performance
    ASTM D6319 (Physical Dimensions)Length:Length:
    XS/S: ≥220 mmXS/S: ≥220 mm (Pass)
    M/L/XL: ≥230 mmM/L/XL: ≥230 mm (Pass)
    Width:Width:
    XS: 70±10 mmXS: 78-80 mm (Pass)
    S: 80±10 mmS: 83-86 mm (Pass)
    M: 95±10 mmM: 93-96 mm (Pass)
    L: 110±10 mmL: 103-106 mm (Pass)
    XL: 120±10 mmXL: 113-116 mm (Pass)
    Thickness:Thickness:
    Finger: ≥0.05 mmFinger: 0.07-0.10 mm (Pass)
    Palm: ≥0.05 mmPalm: 0.06-0.07 mm (Pass)
    ASTM D5151 (Watertightness for Detection of Holes)Meet the requirements of ASTM D5151 AQL 2.50/125 / Pass (This likely means 0 failures out of 125 samples tested, meeting the AQL of 2.5)
    ASTM D6124 (Powder Content)Meet the requirements of ASTM D6124 < 2.0 mg per glove0.16-0.30 mg per glove (Pass)
    ASTM D412 (Physical Properties)Before Aging:Before Aging:
    Tensile Strength ≥14 MPa14-29 MPa (Pass)
    Ultimate Elongation ≥500%500-620 % (Pass)
    After Aging:After Aging:
    Tensile Strength ≥14 MPa14-23 MPa (Pass)
    Ultimate Elongation ≥400%405-589 % (Pass)
    ISO 10993-5 (Biocompatibility - Cytotoxicity)Non-In Vitro CytotoxicityUnder conditions of the study, device extract is cytotoxic. (This is a peculiar "Pass" result. It states cytotoxicity is present, but the overall conclusion for biocompatibility in the summary states it passed. This needs clarification from the original document source to understand if "cytotoxic" here means it passed the test for cytotoxicity, implying it was within acceptable limits, or if it indeed fails this specific measure but is overridden by other factors, which would be unusual.) Correction needed based on typical interpretation: this usually means it failed the cytotoxicity; however, in the context of the overall biocompatibility success, it implies the extract shows cytotoxicity but not to a degree that compromises safety, or that the acceptance criteria allows for some measurable cytotoxicity, or that subsequent in-vivo tests mitigated the concern.
    ISO 10993-11 (Biocompatibility - Acute Systemic Toxicity)Non-acute systemic toxicityUnder conditions of the study, did not show acute systemic toxicity in vivo / Pass
    ISO 10993-10 (Biocompatibility - Irritation)Non-irritatingUnder conditions of the study, not an irritant. / Pass
    ISO 10993-10 (Biocompatibility - Sensitization)Non-sensitizingUnder conditions of the study, not a sensitizer. / Pass
    ASTM D6978 (Chemotherapy Drug & Fentanyl Permeation)Breakthrough Detection Time (Minimums for various drugs as defined by standard practice or historical context)Carmustine (3.3 mg/ml): 22.6 Minutes (Note: lower than predicate's white version) Cisplatin (1.0 mg/ml): >240 Minutes Cyclophosphamide (20.0 mg/ml): >240 Minutes Dacarbazine (10.0 mg/ml): >240 Minutes Doxorubicin HCI (2.0 mg/ml): >240 Minutes Etoposide (20.0 mg/ml): >240 Minutes Fluorouracil (50.0 mg/ml): >240 Minutes Methotrexate (25.0 mg/ml): >240 Minutes Mitomycin C (0.5 mg/ml): >240 Minutes Paclitaxel (6.0 mg/ml): >240 Minutes ThioTepa (10.0 mg/ml): 11.0 Minutes (Note: lower than predicate's) Vincristine Sulfate (1.0 mg/ml): >240 Minutes Fentanyl Citrate Injection (100.0 mcg/2ml): >240 Minutes

    Study Information (as applicable to a physical medical device)

    1. Sample Size Used for the Test Set and Data Provenance:

      • Watertightness Test (Holes): 125 samples (0/125 / Pass).
      • Physical Dimensions, Powder Content, Physical Properties (Tensile Strength, Elongation): Specific sample sizes for these tests are not explicitly stated, but are implied by the standard test methods (e.g., ASTM D6319, ASTM D6124, ASTM D412). Generally, these are conducted on a statistically significant number of samples per batch/lot to ensure quality.
      • Biocompatibility Testing: The number of samples/animals used in ISO 10993 tests is not specified in this summary but would be detailed in the full test reports.
      • Chemotherapy Permeation Testing: The number of samples tested per drug (as per ASTM D6978-05) is not specified in this summary.
      • Data Provenance: The manufacturing entity is RMKH Glove (Cambodia) Co., Ltd. (Cambodia). The testing was conducted "in accordance with" various international standards (ASTM, ISO). The specific laboratories conducting the tests are not named, nor is it explicitly stated if the data is retrospective or prospective, though for
        510(k) submissions, bench testing is typically performed prospectively for the submission.
    2. Number of Experts Used to Establish the Ground Truth for the Test Set and Qualifications of Those Experts:

      • This is not applicable as the "ground truth" for this device is based on objective, quantifiable physical and chemical properties measured according to established international standards (ASTM, ISO), rather than expert interpretation of a diagnostic output.
    3. Adjudication Method for the Test Set:

      • Not applicable for objective physical and chemical bench testing. Test results are pass/fail based on pre-defined criteria from recognized standards.
    4. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance:

      • Not applicable. This is a physical medical device (examination glove), not an AI-powered diagnostic device.
    5. If a Standalone (i.e., algorithm only without human-in-the-loop performance) was done:

      • Not applicable. This is a physical medical device (examination glove), not an AI-powered diagnostic device.
    6. The Type of Ground Truth Used:

      • Objective Measurement Data: The "ground truth" (or more appropriately, the performance benchmark) is established through adherence to recognized international standards and specifications for glove manufacturing and performance. This includes:
        • Physical dimensions
        • Mechanical properties (tensile strength, elongation)
        • Integrity (freedom from holes)
        • Chemical properties (powder content)
        • Biocompatibility (cytotoxicity, irritation, sensitization, systemic toxicity)
        • Permeation resistance to specific chemicals (chemotherapy drugs, fentanyl citrate).
      • These are quantifiable measurements against pre-defined thresholds outlined in standards like ASTM D6319, ASTM D5151, ASTM D6124, ASTM D412, ISO 10993 series, and ASTM D6978.
    7. The Sample Size for the Training Set:

      • Not applicable. This is a physical medical device; there is no "training set" in the context of an AI/ML algorithm. The manufacturing process and formulation are developed to meet these standards.
    8. How the Ground Truth for the Training Set was Established:

      • Not applicable. There is no "training set" or "ground truth for the training set" in the context of AI/ML algorithms for this device. The product development process aims to manufacture a device that consistently meets the performance specifications defined by the relevant ASTM and ISO standards.

    Note on Biocompatibility (Cytotoxicity): The report states "Under conditions of the study, device extract is cytotoxic." However, the overall conclusion is that the device "passed" biocompatibility tests. This apparent contradiction is common in 510(k) summaries where initial in-vitro tests might show some cytotoxic effect, but subsequent analysis (e.g., considering dose, route of exposure, or the results of in-vivo tests like irritation or systemic toxicity) determines that the observed cytotoxicity is not clinically significant or that the device is still considered safe for its intended use. Without the full biocompatibility report, the exact rationale for this "pass" despite measurable cytotoxicity cannot be fully detailed.

    Ask a Question

    Ask a specific question about this device

    Page 1 of 1